APA (7th ed.) Citation

BY, C., Q, C., XT, M., K, O., WW, Y., LT, Z., . . . L, Y. (2025). Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer. BMC cancer, 25(1), 449. https://doi.org/10.1186/s12885-025-13799-5

Chicago Style (17th ed.) Citation

BY, Cao, et al. "Efficacy and Safety of Triplet Regimen Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) as First-line Chemotherapy for Advanced Pancreatic Cancer." BMC Cancer 25, no. 1 (2025): 449. https://doi.org/10.1186/s12885-025-13799-5.

MLA (9th ed.) Citation

BY, Cao, et al. "Efficacy and Safety of Triplet Regimen Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) as First-line Chemotherapy for Advanced Pancreatic Cancer." BMC Cancer, vol. 25, no. 1, 2025, p. 449, https://doi.org/10.1186/s12885-025-13799-5.